Zacks Research Issues Pessimistic Forecast for VRTX Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) – Zacks Research reduced their Q1 2025 earnings per share (EPS) estimates for Vertex Pharmaceuticals in a note issued to investors on Thursday, January 23rd. Zacks Research analyst R. Department now expects that the pharmaceutical company will post earnings of $3.51 per share for the quarter, down from their prior forecast of $3.82. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is ($1.90) per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ Q2 2025 earnings at $3.76 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last announced its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. The firm had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.67 earnings per share.

Other research analysts also recently issued research reports about the company. Citigroup initiated coverage on Vertex Pharmaceuticals in a report on Thursday, November 14th. They issued a “buy” rating and a $575.00 price objective on the stock. Stifel Nicolaus lifted their price objective on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a “hold” rating in a research report on Monday, December 16th. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Friday, December 20th. Barclays reduced their price objective on shares of Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating for the company in a research note on Friday, December 20th. Finally, Scotiabank lifted their price objective on Vertex Pharmaceuticals from $426.00 to $430.00 and gave the stock a “sector perform” rating in a report on Monday, December 23rd. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $494.76.

Check Out Our Latest Stock Analysis on VRTX

Vertex Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ:VRTX opened at $440.68 on Monday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average price is $434.90 and its 200 day moving average price is $463.98. The stock has a market cap of $113.49 billion, a price-to-earnings ratio of -221.45, a price-to-earnings-growth ratio of 2.20 and a beta of 0.40. Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88.

Institutional Trading of Vertex Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Northwest Investment Counselors LLC purchased a new position in Vertex Pharmaceuticals in the 3rd quarter worth approximately $25,000. Highline Wealth Partners LLC bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth about $27,000. Dunhill Financial LLC raised its stake in Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 24 shares in the last quarter. Brown Lisle Cummings Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at approximately $30,000. Finally, Legacy Investment Solutions LLC bought a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth about $33,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

About Vertex Pharmaceuticals

(Get Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Featured Articles

Earnings History and Estimates for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.